Neoprobe initiates Phase III cancer trial
The Phase III study will evaluate the efficacy of Lymphoseek to identify lymph nodes that may be predictive of determining whether a patient’s cancer has spread into the
The US Food and Drug Administration (FDA) has granted priority review to Roche’s supplemental biologics licence application (sBLA) for Gazyva/Gazyvaro (obinutuzumab) to treat adults with primary membranous nephropathy (pMN).
GPI-04-0001 is a Phase IIb, non-randomized, open-label, single-arm international, multi-center registration study designed to evaluate the efficacy, safety and tolerability of romidepsin as a treatment for cutaneous T-cell